{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T22:37:35Z","timestamp":1790807855771,"version":"4.1.0"},"reference-count":33,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2018,7,1]],"date-time":"2018-07-01T00:00:00Z","timestamp":1530403200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,7,1]],"date-time":"2018-07-01T00:00:00Z","timestamp":1530403200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["ajkd.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Kidney Diseases"],"published-print":{"date-parts":[[2018,7]]},"DOI":"10.1053\/j.ajkd.2017.11.019","type":"journal-article","created":{"date-parts":[[2018,2,9]],"date-time":"2018-02-09T01:22:17Z","timestamp":1518139337000},"page":"84-92","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":147,"title":["Patterns of Clinical Response to Eculizumab in Patients With C3 Glomerulopathy"],"prefix":"10.1053","volume":"72","author":[{"given":"Moglie","family":"Le Quintrec","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne-Laure","family":"Lapeyraque","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arnaud","family":"Lionet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne-Laure","family":"Sellier-Leclerc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yahsou","family":"Delmas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V\u00e9ronique","family":"Baudouin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Daugas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"St\u00e9phane","family":"Decramer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leila","family":"Tricot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathilde","family":"Cailliez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Dubot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aude","family":"Servais","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Mourey-Epron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franck","family":"Pourcine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chantal","family":"Loirat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V\u00e9ronique","family":"Fr\u00e9meaux-Bacchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fadi","family":"Fakhouri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1053\/j.ajkd.2017.11.019_bib1","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1038\/ng912","article-title":"Uncontrolled C3 activation causes membranoproliferative glomerulonephritis in mice deficient in complement factor H","volume":"31","author":"Pickering","year":"2002","journal-title":"Nat Genet"},{"issue":"4","key":"10.1053\/j.ajkd.2017.11.019_bib2","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1038\/ki.2012.63","article-title":"Acquired and genetic complement abnormalities play a critical role in dense deposit disease and other C3 glomerulopathies","volume":"82","author":"Servais","year":"2012","journal-title":"Kidney Int"},{"issue":"4","key":"10.1053\/j.ajkd.2017.11.019_bib3","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1038\/ki.2012.212","article-title":"C3 glomerulonephritis: clinicopathological findings, complement abnormalities, glomerular proteomic profile, treatment, and follow-up","volume":"82","author":"Sethi","year":"2012","journal-title":"Kidney Int"},{"issue":"24","key":"10.1053\/j.ajkd.2017.11.019_bib4","doi-asserted-by":"crossref","first-page":"2340","DOI":"10.1056\/NEJMc1107484","article-title":"Combined C3b and factor B autoantibodies and MPGN type II","volume":"365","author":"Chen","year":"2011","journal-title":"N\u00a0Engl J Med"},{"issue":"5","key":"10.1053\/j.ajkd.2017.11.019_bib5","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1681\/ASN.2016030343","article-title":"Anti-factor B and anti-C3b autoantibodies in C3 glomerulopathy and Ig-associated membranoproliferative GN","volume":"28","author":"Marinozzi","year":"2017","journal-title":"J\u00a0Am Soc Nephrol"},{"issue":"8","key":"10.1053\/j.ajkd.2017.11.019_bib6","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1038\/nrneph.2010.85","article-title":"C3 glomerulopathy: a new classification","volume":"6","author":"Fakhouri","year":"2010","journal-title":"Nat Rev Nephrol"},{"issue":"6","key":"10.1053\/j.ajkd.2017.11.019_bib7","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1038\/ki.2013.377","article-title":"C3 glomerulopathy: consensus report","volume":"84","author":"Pickering","year":"2013","journal-title":"Kidney Int"},{"issue":"1","key":"10.1053\/j.ajkd.2017.11.019_bib8","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1007\/s00467-015-3310-4","article-title":"C3 glomerulopathy","volume":"32","author":"Riedl","year":"2017","journal-title":"Pediatr Nephrol"},{"issue":"23","key":"10.1053\/j.ajkd.2017.11.019_bib9","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1056\/NEJMoa1208981","article-title":"Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome","volume":"368","author":"Legendre","year":"2013","journal-title":"N\u00a0Engl J Med"},{"issue":"3","key":"10.1053\/j.ajkd.2017.11.019_bib10","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.smim.2016.06.002","article-title":"Complement inhibition in C3 glomerulopathy","volume":"28","author":"Nester","year":"2016","journal-title":"Semin Immunol"},{"issue":"5","key":"10.1053\/j.ajkd.2017.11.019_bib11","doi-asserted-by":"crossref","first-page":"748","DOI":"10.2215\/CJN.12901211","article-title":"Eculizumab for dense deposit disease and C3 glomerulonephritis","volume":"7","author":"Bomback","year":"2012","journal-title":"Clin J Am Soc Nephrol"},{"issue":"12","key":"10.1053\/j.ajkd.2017.11.019_bib12","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1056\/NEJMc1112273","article-title":"Eculizumab in a patient with dense-deposit disease","volume":"366","author":"Daina","year":"2012","journal-title":"N\u00a0Engl J Med"},{"issue":"12","key":"10.1053\/j.ajkd.2017.11.019_bib13","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1056\/NEJMc1111953","article-title":"Eculizumab for the treatment of dense-deposit disease","volume":"366","author":"Vivarelli","year":"2012","journal-title":"N\u00a0Engl J Med"},{"issue":"4","key":"10.1053\/j.ajkd.2017.11.019_bib14","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1007\/s00467-015-3306-0","article-title":"Discontinuation of dialysis with eculizumab therapy in a pediatric patient with dense deposit disease","volume":"31","author":"Tran","year":"2016","journal-title":"Pediatr Nephrol"},{"issue":"10","key":"10.1053\/j.ajkd.2017.11.019_bib15","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.2215\/CJN.01360215","article-title":"Eculizumab in pediatric dense deposit disease","volume":"10","author":"Oosterveld","year":"2015","journal-title":"Clin J Am Soc Nephrol"},{"issue":"3","key":"10.1053\/j.ajkd.2017.11.019_bib16","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1053\/j.ajkd.2014.09.025","article-title":"Eculizumab for treatment of rapidly progressive C3 glomerulopathy","volume":"65","author":"Le Quintrec","year":"2015","journal-title":"Am J Kidney Dis"},{"issue":"7","key":"10.1053\/j.ajkd.2017.11.019_bib17","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1007\/s00467-013-2748-5","article-title":"Eculizumab therapy in a patient with dense-deposit disease associated with partial lipodystropy","volume":"29","author":"Ozkaya","year":"2014","journal-title":"Pediatr Nephrol"},{"issue":"1","key":"10.1053\/j.ajkd.2017.11.019_bib18","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1186\/s13000-016-0547-6","article-title":"Severe active C3 glomerulonephritis triggered by immune complexes and inactivated after eculizumab therapy","volume":"11","author":"Kersnik Levart","year":"2016","journal-title":"Diagn Pathol"},{"issue":"5","key":"10.1053\/j.ajkd.2017.11.019_bib19","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1038\/ki.2014.423","article-title":"Efficacy and safety of eculizumab in atypical hemolytic uremic syndrome from 2-year extensions of phase 2 studies","volume":"87","author":"Licht","year":"2015","journal-title":"Kidney Int"},{"issue":"1","key":"10.1053\/j.ajkd.2017.11.019_bib20","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1053\/j.ajkd.2015.12.034","article-title":"Terminal complement inhibitor eculizumab in adult patients with atypical hemolytic uremic syndrome: a single-arm, open-label trial","volume":"68","author":"Fakhouri","year":"2016","journal-title":"Am J Kidney Dis"},{"issue":"3","key":"10.1053\/j.ajkd.2017.11.019_bib21","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1016\/j.kint.2015.11.026","article-title":"Eculizumab is a safe and effective treatment in pediatric patients with atypical hemolytic uremic syndrome","volume":"89","author":"Greenbaum","year":"2016","journal-title":"Kidney Int"},{"issue":"6","key":"10.1053\/j.ajkd.2017.11.019_bib22","doi-asserted-by":"crossref","first-page":"461","DOI":"10.7326\/0003-4819-130-6-199903160-00002","article-title":"A\u00a0more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group","volume":"130","author":"Levey","year":"1999","journal-title":"Ann Intern Med"},{"issue":"3","key":"10.1053\/j.ajkd.2017.11.019_bib23","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1681\/ASN.2008030287","article-title":"New equations to estimate GFR in children with CKD","volume":"20","author":"Schwartz","year":"2009","journal-title":"J\u00a0Am Soc Nephrol"},{"issue":"4","key":"10.1053\/j.ajkd.2017.11.019_bib24","doi-asserted-by":"crossref","first-page":"554","DOI":"10.2215\/CJN.04760512","article-title":"Genetics and outcome of atypical hemolytic uremic syndrome: a nationwide French series comparing children and adults","volume":"8","author":"Fremeaux-Bacchi","year":"2013","journal-title":"Clin J Am Soc Nephrol"},{"issue":"5","key":"10.1053\/j.ajkd.2017.11.019_bib25","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1016\/j.kint.2017.04.017","article-title":"C5 nephritic factors drive the biological phenotype of C3 glomerulopathies","volume":"92","author":"Marinozzi","year":"2017","journal-title":"Kidney Int"},{"issue":"3","key":"10.1053\/j.ajkd.2017.11.019_bib26","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/j.kint.2016.10.005","article-title":"Atypical hemolytic uremic syndrome and C3 glomerulopathy: conclusions from a \u201cKidney Disease: Improving Global Outcomes\u201d (KDIGO) Controversies Conference","volume":"91","author":"Goodship","year":"2017","journal-title":"Kidney Int."},{"issue":"6","key":"10.1053\/j.ajkd.2017.11.019_bib27","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1007\/s00467-017-3619-2","article-title":"C3 glomerulopathy and eculizumab: a report on four paediatric cases","volume":"32","author":"Lebreton","year":"2017","journal-title":"Pediatr Nephrol"},{"issue":"6","key":"10.1053\/j.ajkd.2017.11.019_bib28","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1007\/s00467-013-2711-5","article-title":"Rituximab fails where eculizumab restores renal function in C3nef-related DDD","volume":"29","author":"Rousset-Rouviere","year":"2014","journal-title":"Pediatr Nephrol"},{"issue":"6","key":"10.1053\/j.ajkd.2017.11.019_bib29","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1007\/s00467-015-3061-2","article-title":"A\u00a0case of C3 glomerulonephritis successfully treated with eculizumab","volume":"30","author":"Payette","year":"2015","journal-title":"Pediatr Nephrol"},{"issue":"25","key":"10.1053\/j.ajkd.2017.11.019_bib30","doi-asserted-by":"crossref","first-page":"9649","DOI":"10.1073\/pnas.0601094103","article-title":"Prevention of C5 activation ameliorates spontaneous and experimental glomerulonephritis in factor H-deficient mice","volume":"103","author":"Pickering","year":"2006","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"4","key":"10.1053\/j.ajkd.2017.11.019_bib31","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1093\/ckj\/sfv044","article-title":"Eculizumab-induced reversal of dialysis-dependent kidney failure from C3 glomerulonephritis","volume":"8","author":"Inman","year":"2015","journal-title":"Clin Kidney J"},{"issue":"5","key":"10.1053\/j.ajkd.2017.11.019_bib32","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1038\/ki.2015.227","article-title":"Effectiveness of mycophenolate mofetil in C3 glomerulonephritis","volume":"88","author":"Rabasco","year":"2015","journal-title":"Kidney Int"},{"issue":"21","key":"10.1053\/j.ajkd.2017.11.019_bib33","doi-asserted-by":"crossref","first-page":"3253","DOI":"10.1182\/blood-2014-09-600411","article-title":"Eculizumab reduces complement activation, inflammation, endothelial damage, thrombosis, and renal injury markers in aHUS","volume":"125","author":"Cofiell","year":"2015","journal-title":"Blood"}],"container-title":["American Journal of Kidney Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0272638617311393?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0272638617311393?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T03:12:01Z","timestamp":1759461121000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0272638617311393"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7]]},"references-count":33,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,7]]}},"alternative-id":["S0272638617311393"],"URL":"https:\/\/doi.org\/10.1053\/j.ajkd.2017.11.019","relation":{},"ISSN":["0272-6386"],"issn-type":[{"value":"0272-6386","type":"print"}],"subject":[],"published":{"date-parts":[[2018,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Patterns of Clinical Response to Eculizumab in Patients With C3 Glomerulopathy","name":"articletitle","label":"Article Title"},{"value":"American Journal of Kidney Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.ajkd.2017.11.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 by the National Kidney Foundation, Inc. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}